Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.
Memento Medicines has raised $93.0M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
Memento Medicines's investors include RA Capital Management, Samsara BioCapital, Forbion Capital Partners, Sanofi Ventures, Avego Bioscience Capital.
Memento Medicines is headquartered in Chester, United Kingdom.
Memento Medicines is a biotech developing bispecific antibody therapies for eye diseases.
Memento Medicines is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Memento Medicines — Funding & Investors." VCBacked, June 18, 2026, https://www.vcbacked.co/company/memento-medicines. Accessed August 21, 2026.
VCBacked. (2026). Memento Medicines — Funding & Investors. Retrieved August 21, 2026, from https://www.vcbacked.co/company/memento-medicines
{{cite web |title=Memento Medicines — Funding & Investors |url=https://www.vcbacked.co/company/memento-medicines |website=VCBacked |access-date=August 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated